Post-molar Choriocarcinoma Prevention with MTX Treatment of Persistent Trophoblastic Disease

Abstract

Aim: Prevention of post molar choriocarcinoma. Methods: 70 mg Methotrexate (MTX) was administered all post molar cases, whose urinary pregnancy test was negative, while 200-300 mg MTX was administered to two persistent trophoblastic disease, whose pregnancy test was positive by human chorionic gonadotropin (hCG). Control was 37 post molar cases, who received no MTX. Post molar examination were repeated in both groups. Results: No choriocarcinoma developed in 107 MTX group, while 3 cases developed choriocarcinoma in 37 nonMTX group. Choriocarcinoma case number was significantly less in MTX groups.